We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
신규 편입 · 포트폴리오 비중 0.03%
신규 편입 · 포트폴리오 비중 0.00%
US analyst rating / recommendation change.
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $41.94 · 12 analysts
Stored first · Google News · Yahoo Finance (English)
LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42 - Moomoo
LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42 Moomoo
(AVBP) Volatility Zones as Tactical Triggers - Stock Traders Daily
(AVBP) Volatility Zones as Tactical Triggers Stock Traders Daily
AVBP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AVBP Earning Date, Earning Analysis and Earning Prediction Intellectia AI
AVBP Q1 2026 Earnings: EPS Miss Highlights Development Stage Challenges - EPS Growth Rate - DonanımHaber
AVBP Q1 2026 Earnings: EPS Miss Highlights Development Stage Challenges - EPS Growth Rate DonanımHaber
ArriVent BioPharma, Inc. Financial Disclosures & SEC Filings - TradingView
ArriVent BioPharma, Inc. Financial Disclosures & SEC Filings TradingView
Price-Driven Insight from (AVBP) for Rule-Based Strategy - Stock Traders Daily
Price-Driven Insight from (AVBP) for Rule-Based Strategy Stock Traders Daily
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 11. | After market close (AMC) | $-0.98 | — | — | $0 | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 14. | Citigroup | — | Maintain | Buy → Buy | — | Citigroup: Buy |
| 2026. 04. 24. | Citigroup | — | Maintain | Buy → Buy | — | Citigroup: Buy |
| 2026. 03. 24. | B. Riley Securities | — | Maintain | Buy → Buy | — | B. Riley Securities: Buy |
| 2026. 03. 07. | Oppenheimer | — | Maintain | Outperform → Outperform | — | Oppenheimer: Outperform |
| 2026. 03. 07. | Citigroup | — | Maintain | Buy → Buy | — | Citigroup: Buy |
| 2026. 03. 06. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 748,195 | $17.26M | 0.03% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 216,660 | $4.36M | 0.01% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 77,479 | $1.56M | 0.00% | — | New position |
| 4 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 48,682 | $1.12M | 0.00% | — | New position |